Obesity Treatment
60 articles on Obesity Treatment, written by Shotlee and medically reviewed for clinical accuracy.
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
Cannabis for Weight Loss: Could It Be the Next Ozempic?
Researchers at UC Riverside have uncovered promising data linking cannabis oil to improved metabolic function and weight loss in mice, sparking debate about its potential as a future therapy alongside GLP-1 medications.
8 min read
Pharmac Funding for Wegovy: What NZ Patients Need to Know
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
8 min read
Eli Lilly: The Obesity Stock to Buy and Hold for Durability
The weight management sector is a multi-billion dollar market today, not a future opportunity. Eli Lilly, with its groundbreaking tirzepatide (Zepbound), is poised for sustained growth and profitability, making it a compelling investment for those prioritizing durability and real earnings.
7 min read
Medicaid GLP-1 Coverage Changes: Access to Ozempic and Wegovy
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
8 min read
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.
2 min read
Duodenal Resurfacing May Prevent Weight Regain After Stopping Ozempic
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
7 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
8 min read
Popular Weight Loss Drugs May Cause Hidden Muscle Loss, Study Finds
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
5 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Retatrutide: Can This Shot Aid Weight Loss and Longevity?
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
4 min read
Fake Retatrutide Weight Loss Drug Flooding Online Market
Counterfeit versions of retatrutide, a promising but unapproved weight loss drug, are flooding online markets despite ongoing phase 3 clinical trials. Experts like obesity specialist Samantha Hocking highlight its potential for 29% body weight loss by targeting GLP-1, GIP, and glucagon. However, doctors and Eli Lilly warn of serious risks from these fake products.
5 min read
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss
A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.
4 min read
GLP-1 Weight Loss Consistent Across Race, Age, BMI—But Not Sex
GLP-1 receptor agonists like semaglutide show consistent weight loss efficacy across diverse groups, but a notable sex difference emerges: women average 10.9% body weight loss versus 6.8% for men. This JAMA meta-analysis reassures clinicians while highlighting areas for further research. Experts explain why this matters for personalized obesity care.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
FDA Approves Foundayo: GLP-1 Weight Loss Pill with Fewer Use Restrictions
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
5 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
6 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
More Americans are turning to GLP-1 drugs like Wegovy for weight loss, but experts warn of a critical error. The biggest mistake, says obesity specialist Dr. Katherine Saunders, is treating the prescription as the full treatment. Pairing meds with healthy habits amplifies benefits and sustains results.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
GLP-1 Drugs Surge: Healthy Habits Still Essential for Best Results
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
6 min read
Study: 10% of Wegovy and Ozempic Users See Minimal Weight Loss
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
5 min read
1 in 10 Wegovy and Ozempic Users Lose Less Than 5% Body Weight
Trials show one in ten people on Wegovy and Ozempic lose less than 5% of their body weight, challenging the drugs' reputation as a universal solution. Patient experiences like Samantha Jess's highlight non-responder realities, while experts explain genetic and metabolic factors. Discover why GLP-1 agonists work for some but not others.
6 min read
ARD-201 Trial: Maintaining Weight Loss After Ozempic, Wegovy
GLP-1 drugs like Ozempic and Wegovy deliver impressive weight loss, but regain is common after stopping. A new Phase 2 trial of oral ARD-201 aims to change that by regulating appetite via bitter taste receptors. Led by obesity expert Lawrence Cheskin at George Mason University, this study targets post-treatment weight maintenance.
5 min read
Behavioral Adherence Tools Key to GLP-1 Weight Loss Success: New Data
As GLP-1 medication use surges, a Weight Watchers report reveals medication alone isn't enough for lasting weight loss. Weight Loss Buddy emerges as a vital tool, combining AI-driven guidance and peer accountability to boost adherence and outcomes. This shift highlights the need for behavioral infrastructure in obesity treatment.
4 min read
Structure's GLP-1 Pill Shows 16% Weight Loss in Phase 2 Trial
Structure Therapeutics announced impressive Phase 2 results for its daily obesity pill, with patients losing about 16% of their body weight compared to placebo after 44 weeks. This positions the company to challenge leaders like Eli Lilly and Novo Nordisk in the race for effective oral GLP-1 therapies. Discover the details and implications for obesity treatment.
4 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
4 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Govt Cautions Pharma Cos on Surrogate Ads for GLP-1 Drugs
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
6 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
Sex-Specific GLP-1 Brain Atlas Reveals Drug Impact Differences
A new peer-reviewed study from Mount Sinai researchers has created the first sex-specific atlas of GLP-1 expression in the mouse brain, revealing dramatic differences between males and females. These insights into drugs like semaglutide and liraglutide could reshape treatments for obesity, diabetes, and even psychiatric disorders. Key hindbrain and olfactory bulb variations highlight why GLP-1 effects on appetite and weight loss differ by sex.
5 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Semaglutide Production Cost: $3/Month Could Expand Access to Obesity & Diabet...
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
5 min read
Study Finds Some Patients Keep Weight Off with Fewer GLP-1 Injections
A new study shows that some patients on GLP-1 drugs like Wegovy can space out injections every other week or longer and still keep weight off. Led by Dr. Mitch Biermann at Scripps Clinic, the research followed 34 patients who maintained health gains after reducing frequency. Experts say this reframes long-term obesity treatment discussions.
5 min read
Tirzepatide Adverse Events: Subgroup Differences Explored
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
5 min read
Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
6 min read
NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
6 min read
Wegovy's Weight Loss Hype Meets Reality: What Americans Should Know
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
6 min read
Study Flags Gut Risks from SNAC in Oral Weight-Loss Pills
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
6 min read
GP's Surprising Mounjaro Effects: Weight Loss and Mood Shifts After 3 Months
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
5 min read
Leicester Doctor's Mounjaro Experience: Mental Changes & Advice
A Leicester doctor tried Mounjaro for obesity and was shocked by how it silenced his 'food noise' and curbed alcohol desires, alongside significant weight loss. But stopping brought cravings back fast. Discover his message on long-term use, side effects, and who should consider it.
5 min read
Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
5 min read
Semaglutide Nasal Spray: Affordable Weight Loss Option Coming Soon
A nasal spray version of semaglutide, the active ingredient in Ozempic and Wegovy, could soon offer an affordable alternative for weight loss. Chinese firm Shanghai Shiling Pharmaceutical is advancing trials, aiming for global markets by 2028 amid soaring demand. This development aligns with Novo Nordisk's upcoming patent loss in China, paving the way for cheaper generics.
5 min read
New GLP-1 Weight-Loss Drugs Stronger Than Wegovy and Zepbound
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
8 min read
Hit Weight Loss Goal on GLP-1s Like Ozempic? What Next?
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have helped 1 in 8 U.S. adults lose 15-20% body weight. But after hitting your goal, what now? Dr. Amy J. Sheer shares proven steps for maintenance, plateaus, and long-term success.
8 min read
GLP-1 Obesity Drugs Complicate Life for People with Disordered Eating
Jason Krynicki, once bullied for obesity, now battles anorexia while on Zepbound, fearing weight regain if he stops. GLP-1 drugs curb appetite effectively but complicate lives for those with disordered eating, often without proper screening. Experts highlight risks and call for caution in a weight-stigma culture.
5 min read
Oral Wegovy Pill: Novo Nordisk's Game-Changer for Obesity
Novo Nordisk's launch of an oral Wegovy pill marks a pivotal shift in GLP-1 therapy, offering a convenient alternative to injections for obesity treatment. This guide explores its mechanism, efficacy, safety profile, and how it stacks up against rivals like Eli Lilly's orforglipron. Learn what this means for your weight loss journey.
4 min read
Wegovy Pill Hits 26K Prescriptions in Week 2: Launch Breakdown
Novo Nordisk's new Wegovy pill has exploded onto the scene, racking up over 26,000 prescriptions in just its second full week. This needle-free GLP-1 option signals a shift in obesity treatment. Discover the data, science, and patient implications behind this rapid uptake.
4 min read
Tirzepatide vs Semaglutide: Weight Loss Duration After Stopping
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
4 min read
Roche CT-388: GLP-1/GIP Shot Rivals Zepbound in Phase 2
Roche is advancing CT-388, a dual GLP-1/GIP agonist, after Phase 2 results showed impressive weight loss comparable to Eli Lilly's Zepbound. With the obesity market booming, can this injectable stand out against Wegovy and emerging orals? Dive into the data and what it means for patients.
4 min read
What Happens When You Stop Ozempic or Wegovy: Expert Insights
Stopping Ozempic or Wegovy often leads to significant weight regain within 1-1.5 years, reversing gains in blood sugar, pressure, and cholesterol. Experts explain the science behind this, from metabolic adaptation to surging appetite. Understand how to approach GLP-1 therapy for long-term success.
4 min read
Medicare GLP-1 Coverage 2026: Wegovy, Zepbound Guide
Medicare is breaking its long-standing rule against covering weight loss drugs like Wegovy and Zepbound through a new GLP-1 initiative. Starting with a bridge phase in July 2026, eligible beneficiaries could pay just $50 monthly copays—if they act now. This guide explains the changes, requirements, and clinical context for GLP-1 therapy.
4 min read